ERBB2 and endometrial cancer: Trastuzumab, an FDA-approved drug which contains monoclonal antibodies targeting the HER-2 receptor extracellular domain, is being tested for endometrial cancer, because in serous endometrial carcinoma the HER-2 gene, which is responsible for the increase of cell proliferation, differentiation, and migration, is overexpressed [11].